{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:30:49Z","timestamp":1791189049226,"version":"4.1.0"},"reference-count":69,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100010354","name":"Hellenic Society of Gastroenterology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010354","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Crohn's and Colitis Organisation (ECCO)"},{"DOI":"10.13039\/501100003132","name":"Agentschap voor Innovatie door Wetenschap en Technologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"UK National Institute for Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1260714N"],"award-info":[{"award-number":["1260714N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G061712"],"award-info":[{"award-number":["G061712"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1111\/apt.13402","type":"journal-article","created":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T02:54:50Z","timestamp":1442199290000},"page":"1158-1169","source":"Crossref","is-referenced-by-count":52,"title":["Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases"],"prefix":"10.1111","volume":"42","author":[{"given":"K.","family":"Papamichael","sequence":"first","affiliation":[{"name":"KU Leuven Department of Pharmaceutical and Pharmacological Sciences; Leuven Belgium"},{"name":"KU Leuven Department of Clinical and Experimental Medicine; Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Van Stappen","sequence":"additional","affiliation":[{"name":"KU Leuven Department of Pharmaceutical and Pharmacological Sciences; Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Jairath","sequence":"additional","affiliation":[{"name":"Translational Gastroenterology Unit; Nuffield Department of Medicine; John Radcliffe Hospital; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Gecse","sequence":"additional","affiliation":[{"name":"1st Department of Medicine; Semmelweis University; Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Khanna","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials Inc.; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"D'Haens","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials Inc.; London ON Canada"},{"name":"Department of Gastroenterology and Hepatology; Academic Medical Centre; University of Amsterdam; Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vermeire","sequence":"additional","affiliation":[{"name":"KU Leuven Department of Clinical and Experimental Medicine; Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gils","sequence":"additional","affiliation":[{"name":"KU Leuven Department of Pharmaceutical and Pharmacological Sciences; Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. G.","family":"Feagan","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials Inc.; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. G.","family":"Levesque","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials Inc.; London ON Canada"},{"name":"Division of Gastroenterology; University of California San Diego; La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Vande Casteele","sequence":"additional","affiliation":[{"name":"KU Leuven Department of Pharmaceutical and Pharmacological Sciences; Leuven Belgium"},{"name":"Division of Gastroenterology; University of California San Diego; La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,13]]},"reference":[{"key":"10.1111\/apt.13402-BIB0001|apt13402-cit-0001","doi-asserted-by":"crossref","first-page":"75e101","DOI":"10.1517\/14712598.2014.858695","article-title":"Targeting TNF-alpha for the treatment of inflammatory bowel disease","volume":"14","author":"Billiet","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1111\/apt.13402-BIB0002|apt13402-cit-0002","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.trsl.2014.09.006","article-title":"Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases","volume":"165","author":"Willrich","year":"2015","journal-title":"Transl Res"},{"key":"10.1111\/apt.13402-BIB0003|apt13402-cit-0003","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/clpt.2011.343","article-title":"The state of the art in the development of biosimilars","volume":"91","author":"McCamish","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/apt.13402-BIB0004|apt13402-cit-0004","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nbt.1839","article-title":"Acceptable changes in quality attributes of glycosylated biopharmaceuticals","volume":"29","author":"Schiestl","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1111\/apt.13402-BIB0005|apt13402-cit-0005","unstructured":"EMA\/CHMP Guideline on similar biological medicinal products http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768"},{"key":"10.1111\/apt.13402-BIB0006|apt13402-cit-0006","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrd984","article-title":"Therapeutic antibodies for human diseases at the dawn of the twenty-first century","volume":"2","author":"Brekke","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/apt.13402-BIB0007|apt13402-cit-0007","unstructured":"EMA\/CHMP\/BMWP Guideline on similar biological medicinal products containing mononclonal antibodies - non-clinical and clinical issues http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500128686.pdf"},{"key":"10.1111\/apt.13402-BIB0008|apt13402-cit-0008","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.4161\/mabs.32221","article-title":"Physicochemical characterization of Remsima","volume":"6","author":"Jung","year":"2014","journal-title":"MAbs"},{"key":"10.1111\/apt.13402-BIB0009|apt13402-cit-0009","unstructured":"EMA\/CHMP Summary of opinion (initial authorisation) of Inflectra http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002778\/WC500144831.pdf"},{"key":"10.1111\/apt.13402-BIB0010|apt13402-cit-0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biologicals.2014.05.005","article-title":"The challenge of indication extrapolation for infliximab biosimilars","volume":"42","author":"Feagan","year":"2014","journal-title":"Biologicals"},{"key":"10.1111\/apt.13402-BIB0011|apt13402-cit-0011","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.autrev.2014.02.004","article-title":"The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper","volume":"13","author":"Fiorino","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1111\/apt.13402-BIB0012|apt13402-cit-0012","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1155\/2013\/327120","article-title":"Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics","volume":"27","author":"Devlin","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"10.1111\/apt.13402-BIB0013|apt13402-cit-0013","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4321\/S1130-01082013000100006","article-title":"Joint position statement by \u201cSociedad Espa\u00f1ola de Patolog\u00eda Digestiva\u201d (Spanish Society of Gastroenterology) and \u201cSociedad Espa\u00f1ola de Farmacolog\u00eda\u201d (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease","volume":"105","author":"Arg\u00fcelles-Arias","year":"2013","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1111\/apt.13402-BIB0014|apt13402-cit-0014","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.dld.2014.07.019","article-title":"Use of biosimilars in inflammatory bowel disease: statements of the Italian Group for Inflammatory Bowel Disease","volume":"46","author":"Annese","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1111\/apt.13402-BIB0015|apt13402-cit-0015","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.crohns.2013.03.011","article-title":"ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)","volume":"7","author":"Danese","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1111\/apt.13402-BIB0016|apt13402-cit-0016","first-page":"26","article-title":"Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases Group (BIRD) (IBD): position document of the Belgian IBD Research & Development","volume":"78","author":"Vermeire","year":"2015","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1111\/apt.13402-BIB0017|apt13402-cit-0017","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1093\/ecco-jcc\/jju027.254","article-title":"5 year budget impact analysis of CT-P13 (Infliximab) for the treatment of Crohn's disease in UK, Italy and France","volume":"9","author":"Kim","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1111\/apt.13402-BIB0018|apt13402-cit-0018","doi-asserted-by":"crossref","first-page":"S427","DOI":"10.1093\/ecco-jcc\/jju027.809","article-title":"Budget impact analysis of introducing biosimilar infliximab for the treatment of gastro intestinal disorders in five European countries","volume":"9","author":"Jha","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1111\/apt.13402-BIB0019|apt13402-cit-0019","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-203198","article-title":"Biosimilars to treat inflammatory arthritis: the challenge of proving identity","volume":"72","author":"Kay","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/apt.13402-BIB0020|apt13402-cit-0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.4161\/mabs.25864","article-title":"Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry","volume":"5","author":"Beck","year":"2013","journal-title":"MAbs"},{"key":"10.1111\/apt.13402-BIB0021|apt13402-cit-0021","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/apt.12477","article-title":"Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases","volume":"38","author":"Rinaudo-Gaujous","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/apt.13402-BIB0022|apt13402-cit-0022","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/MEG.0000000000000098","article-title":"Biosimilars in the therapy of inflammatory bowel diseases","volume":"26","author":"Hlavaty","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/apt.13402-BIB0023|apt13402-cit-0023","first-page":"449","article-title":"Biosimilar Infliximab: an expert view","volume":"150","author":"Genazzani","year":"2015","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1111\/apt.13402-BIB0024|apt13402-cit-0024","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1093\/ecco-jcc\/jju027.153","article-title":"Comparative structural, functional, nonclinical, and phase 1 similarity assessments of PF-06438179, a potential biosimilar to infliximab, and marketed reference products","volume":"9","author":"McClellan","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1111\/apt.13402-BIB0025|apt13402-cit-0025","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/apt.13402-BIB0026|apt13402-cit-0026","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when co-administered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/apt.13402-BIB0027|apt13402-cit-0027","article-title":"Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis","author":"Takeuchi","year":"2015","journal-title":"Mod Rheumatol"},{"key":"10.1111\/apt.13402-BIB0028|apt13402-cit-0028","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.12997","article-title":"Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study","author":"Jung","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/apt.13402-BIB0029|apt13402-cit-0029","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.1093\/ecco-jcc\/jju027.623","article-title":"Biosimilar but not the same","volume":"9","author":"Murphy","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1111\/apt.13402-BIB0030|apt13402-cit-0030","doi-asserted-by":"crossref","first-page":"S382","DOI":"10.1093\/ecco-jcc\/jju027.721","article-title":"Efficacy of the new infliximab biomarker CTP13 induction therapy on mucosal healing in ulcerative colitis patients","volume":"9","author":"Molnar","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1111\/apt.13402-BIB0031|apt13402-cit-0031","doi-asserted-by":"crossref","first-page":"S-865","DOI":"10.1016\/S0016-5085(15)32935-8","article-title":"Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort","volume":"148","author":"Gecse","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.13402-BIB0032|apt13402-cit-0032","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1093\/ecco-jcc\/jju027.158","article-title":"The biosimilars of infliximab are equally well quantified in a clinically validated infliximab assay","volume":"9","author":"Gils","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1111\/apt.13402-BIB0033|apt13402-cit-0033","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease","author":"Vande Casteele","year":"2014","journal-title":"Gut"},{"key":"10.1111\/apt.13402-BIB0034|apt13402-cit-0034","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1097\/MD.0000000000000673","article-title":"Ashkenazi jewish origin protects against formation of antibodies to infliximab and therapy failure","volume":"94","author":"Ungar","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1111\/apt.13402-BIB0035|apt13402-cit-0035","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/gutjnl-2015-309698","article-title":"Immunogenicity to infliximab is associated with HLA-DRB1","volume":"64","author":"Billiet","year":"2015","journal-title":"Gut"},{"key":"10.1111\/apt.13402-BIB0036|apt13402-cit-0036","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2015-309290","article-title":"Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima","author":"Ben-Horin","year":"2015","journal-title":"Gut"},{"key":"10.1111\/apt.13402-BIB0037|apt13402-cit-0037","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/apt.13402-BIB0038|apt13402-cit-0038","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4155\/bio.13.2","article-title":"European perspective on biosimilars","volume":"5","author":"Wadhwa","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1111\/apt.13402-BIB0039|apt13402-cit-0039","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.crohns.2014.01.022","article-title":"ECCO position challenged by European drug regulators","volume":"8","author":"Kurki","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1111\/apt.13402-BIB0040|apt13402-cit-0040","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/0091270008316886","article-title":"Population pharmacokinetics of infliximab in patients with ankylosing spondylitis","volume":"48","author":"Xu","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/apt.13402-BIB0041|apt13402-cit-0041","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","article-title":"Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis","volume":"65","author":"Fasanmade","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/apt.13402-BIB0042|apt13402-cit-0042","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther"},{"key":"10.1111\/apt.13402-BIB0043|apt13402-cit-0043","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1182\/blood-2014-06-583617","article-title":"Biosimilars: the science of extrapolation","volume":"124","author":"Weise","year":"2014","journal-title":"Blood"},{"key":"10.1111\/apt.13402-BIB0044|apt13402-cit-0044","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2012-04-425744","article-title":"Biosimilars: what clinicians should know","volume":"120","author":"Weise","year":"2012","journal-title":"Blood"},{"key":"10.1111\/apt.13402-BIB0045|apt13402-cit-0045","unstructured":"Biologics Price Competition and Innovation Act of 2009 (BPCI Act) 2010 http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatory%20Information\/UCM216146.pdf"},{"key":"10.1111\/apt.13402-BIB0046|apt13402-cit-0046","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1093\/ecco-jcc\/jju027.413","article-title":"Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients","volume":"9","author":"Jarzebicka","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1111\/apt.13402-BIB0047|apt13402-cit-0047","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s10620-014-3392-z","article-title":"Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series","volume":"60","author":"Kang","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1111\/apt.13402-BIB0048|apt13402-cit-0048","unstructured":"European Public Assessment Report Remicade - Annex I Summary of Product Characteristics http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Product_Information\/human\/000240\/WC500050888.pdf"},{"key":"10.1111\/apt.13402-BIB0049|apt13402-cit-0049","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.13402-BIB0050|apt13402-cit-0050","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2036.2004.01871.x","article-title":"Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease","volume":"19","author":"Louis","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/apt.13402-BIB0051|apt13402-cit-0051","unstructured":"Health Canada Summary Basis of Decision-REMSIMA http:\/\/www.hc-sc.gc.ca\/dhp-mps\/prodpharma\/sbd-smd\/drug-med\/sbd_smd_2014_remsima_160195-eng.php"},{"key":"10.1111\/apt.13402-BIB0052|apt13402-cit-0052","unstructured":"Health Canada Summary Basis of Decision-INFLECTRA http:\/\/www.hc-sc.gc.ca\/dhp-mps\/prodpharma\/sbd-smd\/drug-med\/sbd_smd_2014_inflectra_159493-eng.php"},{"key":"10.1111\/apt.13402-BIB0053|apt13402-cit-0053","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1007\/s10620-015-3581-4","article-title":"Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn's disease patients failing infliximab","volume":"60","author":"Steenholdt","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1111\/apt.13402-BIB0054|apt13402-cit-0054","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.13402-BIB0055|apt13402-cit-0055","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s11894-014-0378-0","article-title":"Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives","volume":"16","author":"Vande Casteele","year":"2014","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1111\/apt.13402-BIB0056|apt13402-cit-0056","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s10620-015-3673-1","article-title":"Preemptive dose optimization using therapeutic drug monitoring for biologic therapy of Crohn's disease: avoiding failure while lowering costs?","volume":"60","author":"Vande Casteele","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1111\/apt.13402-BIB0057|apt13402-cit-0057","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1517\/14712598.7.7.1051","article-title":"Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases","volume":"7","author":"Tilg","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"10.1111\/apt.13402-BIB0058|apt13402-cit-0058","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/apt.13402-BIB0059|apt13402-cit-0059","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.13402-BIB0060|apt13402-cit-0060","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/gutjnl-2012-303824","article-title":"Biosimilars in IBD: hope or expectation?","volume":"62","author":"Gecse","year":"2013","journal-title":"Gut"},{"key":"10.1111\/apt.13402-BIB0061|apt13402-cit-0061","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crohns.2014.02.007","article-title":"Biosimilars: in support of extrapolation of indications","volume":"8","author":"Ebbers","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1111\/apt.13402-BIB0062|apt13402-cit-0062","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40259-014-0094-1","article-title":"A review of CT-P13: an infliximab biosimilar","volume":"28","author":"McKeage","year":"2014","journal-title":"BioDrugs"},{"key":"10.1111\/apt.13402-BIB0063|apt13402-cit-0063","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1208\/s12248-013-9534-y","article-title":"Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?","volume":"16","author":"Lee","year":"2014","journal-title":"AAPS J"},{"key":"10.1111\/apt.13402-BIB0064|apt13402-cit-0064","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1111\/apt.13402-BIB0065|apt13402-cit-0065","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/apt.13402-BIB0066|apt13402-cit-0066","first-page":"841","article-title":"Chimeric antitumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy","volume":"27","author":"Kavanaugh","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1111\/apt.13402-BIB0067|apt13402-cit-0067","first-page":"13","article-title":"Clinical pharmacokinetics of tumor necrosis factor antagonists","volume":"74","author":"Nestorov","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1111\/apt.13402-BIB0068|apt13402-cit-0068","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1093\/ecco-jcc\/jju027.549","article-title":"Assessment of safety and efficacy of biosimilar infliximab in children with Crohn disease: a preliminary report","volume":"9","author":"Sieczkowska","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1111\/apt.13402-BIB0069|apt13402-cit-0069","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1093\/ecco-jcc\/jju027.574","article-title":"First observations of the use of biosimilar infliximab for treatment of ulcerative colitis in paediatric population","volume":"9","author":"Jarzebicka","year":"2015","journal-title":"J Crohns Colitis"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13402","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/apt.13402\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T16:29:03Z","timestamp":1625416143000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.13402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,13]]},"references-count":69,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,11]]}},"URL":"https:\/\/doi.org\/10.1111\/apt.13402","archive":["Portico"],"relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9,13]]}}}